Prescient is an evidence-based decision-support partner to the pharmaceutical and biotech industries whose mission is to optimally shape new product, brand and mature product planning strategies.

Our diverse yet integrated skillsets and methodologies ensure our clients’ key decisions are objectively assessed from both a clinical and commercial perspective, resulting in differentiated products and offerings.


Shaping Decisions Driving Value

Our People

Prescient’s team consists of highly experienced executives who share our core values of thinking collaboratively, creatively and constructively. We effectively integrate different skills and perspectives into a single client-engagement team.

Our Approach

The format and scope of our engagements are customized to meet our clients’ needs and our ‘best-in-front’ team philosophy ensures access to the necessary levels of expertise and thinking.

Our Clients

We engage directly with a number of functions supporting new product, brand and mature product planning activities; to view a full list of these, please click the
link below.

Latest News

Study suggests new drug candidate could treat both type 2 diabetes and bone loss

Merck receives Breakthrough Therapy Designation from FDA and PRIME status from EMA for investigation …

FDA updates warnings for fluoroquinolone antibiotics

Male hormone reverses cell aging in clinical trial

Roche delivers continued growth in the first half of 2016

Combining new and old drugs improves survival for soft-tissue cancer patients

The European Stroke Organisation and Boehringer Ingelheim launch the "Angels Initiative"

Anti-tumor antibodies could counter atherosclerosis

Pfizer receives World Health Organization prequalification for multi-dose vial presentation of Preve …

Moderate exercise might be more effective at combatting pre-diabetes

Zika epidemic likely to end within 3 years

Amgen and Daiichi Sankyo announce agreement to commercialize biosimilars in Japan

Losing weight lowered levels of proteins associated with tumor growth

Boehringer Ingelheim and Lilly announce clinical trial collaboration in metastatic breast cancer

Pomegranate finally reveals its powerful anti-aging secret

BioMarin up on positive gene therapy data in hemophilia A

After Pfizer buyout, VCs back team with $55M for next specialty pharma

GSK pays up to $230M on J&J deal for asthma antibody

Waksal's Kadmon IPO crumbles after raising $75M

Astellas boosts funding, involvement in updated Cytokinetics collab

TauRx misses primary endpoints in Alzheimer’s combo PhIII trial

Merck shocks ALK by returning rights to allergy immunotherapies

U.S. wary on biotech advances; gene editing, CRISPR ‘raising urgency’

The top women in biopharma for 2016: A call for nominations

Kite nabs engineered allogeneic T-cell tech from UCLA

Microcap Tokai tumbles on discontinued pivotal trial

Cash-rich Moderna to begin first AstraZeneca trial under collab deal

J&J, Genmab bag breakthrough status for Darzalex, shortening route to second-line use

Newron to resubmit troubled Parkinson’s drug to FDA; abuse risks cleared

Ex-Amgen team nabs $14M from Merck, Gates Foundation for cheap biologics

NICE issues decisions on leukemia, melanoma and cystic fibrosis drugs

GSK sees 4% rise in second quarter sales

GSK in-licenses MAb asthma drug candidate from Janssen

Newron and partners to re-submit US NDA for Xadago

Elliot Goldstein, CEO of ProMIS Neurosciences, on moving the Alzheimer’s goalposts

David Ricks to head Eli Lilly, as John Lechleiter is set to retire

Tokai shares decimated by halting of Phase III galeterone trial in prostate cancer

Biotech startup challenges Bayer's Stivarga patent

ALK shares slide as Merck & Co ends partnership

Bayer beats expectations in 2nd-qtr results; raises guidance

Celgene’s Revlimid fails to meet Phase III endpoint for expanded indication

BIND Therapeutics says Pfizer’s $40 million bid for its assets is the winner

Dr Reddy’s post 14% 1st-qtr FY2017 sales decline

Three leading therapy areas make up 68% of pharma pipeline; report

GSK confirms post-Brexit UK still attractive, with £275 million in manufacturing network

Medical News Today: Ketone drink may help athletes unlock greater human metabolic potential

Medical News Today: E-cigarettes: Toxic emission level dependent on temperature, type, age of device

Medical News Today: Acetaminophen: Is it as safe as we think?

Medical News Today: Mono: What are the Early Signs and Symptoms?

Medical News Today: Transgender identity 'should not be classified as a mental disorder'

Medical News Today: Hand, Foot, and Mouth Disease: What to Expect

Medical News Today: The dangers of physical inactivity revisited in 45-year study

Medical News Today: Colorectal cancer: Minimally invasive, triple-therapy patch destroys tumors

Medical News Today: Decline in U.S. early term birth rates, labor induction, cesarean delivery

Medical News Today: Aging accelerated by menopause, insomnia

Medical News Today: Dysplasia: What You Need to Know

Medical News Today: Breast cancer risk may be influenced by type of fat dad eats

Medical News Today: High numbers of black youths killed by police 'reflect excess exposure …

Medical News Today: What are the Symptoms of a Blood Clot?

Medical News Today: Labor induction: No association with autism

Dynamic and different L%26D prospect for Pharma marketers and teams

Time is running out to enter Sales Manager of the Year 2016

GSK invests £275m in UK manufacturing

Nerve stimulation reduces impact of migraine

Top three therapy areas dominate pipelines

Boehringer stops Gilotrif trials

CHMP nod for Allergan's IBS-D drug

Sanofi Pasteur MSD's four-strain flu vaccine approved

NICE approves Servier’s Lonsurf as third-line cancer therapy

Anti-malaria drug could help fight cancer

Shire’s pancreatic cancer drug gets EMA nod

Breakthrough status for Pfizer/Spark haemophilia gene therapy

Study data back efficacy of AZ novel antibiotic

Shire launches immunodeficiency drug for children

US delay to Merck’s C.difficile antitoxin

More News